Earnings History Data for Inovio Pharmaceuticals, Inc. (INO) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
14-11-2024	AH		INO	Inovio Pharmaceuticals, Inc.	133.72	-0.89	-1.20	-1.08	Inovio Pharmaceuticals Non-GAAP EPS of -$0.89 beats by $0.24 [11/14/2024 4:08 PM]	4.26	-0.51 (-10.69%)	4.87	0.10 (2.10%)	4.20 - 14.75	633,897	370,000	903
Inovio Pharmaceuticals Non-GAAP EPS of -$0.89 beats by $0.24 [11/14/2024 4:08 PM] Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial [Nov-13-24 08:00AM] INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights [2024-11-14 04:05PM]
08-08-2024	AH		INO	Inovio Pharmaceuticals, Inc.	224.65	-1.19	-1.15	-1.56	Inovio Pharmaceuticals GAAP EPS of -$1.19 misses by $0.09, revenue of $0.1M misses by $0.02M [8/8/2024 4:08 PM]	8.31	-0.40 (-4.54%)	8.55	-0.16 (-1.84%)	3.89 - 14.75	418,236	290,000	5,152
Inovio Pharmaceuticals GAAP EPS of -$1.19 misses by $0.09, revenue of $0.1M misses by $0.02M [8/8/2024 4:08 PM]
13-05-2024	AH		INO	Inovio Pharmaceuticals, Inc.	261.28	-1.31	-1.08	-1.92	Inovio Pharmaceuticals GAAP EPS of -$1.31 misses by $0.31 [5/13/2024 4:07 PM]	11.43	0.07 (0.62%)	11.50	0.14 (1.23%)	3.89 - 14.75	384,581	260,000	5,230
Inovio Pharmaceuticals GAAP EPS of -$1.31 misses by $0.31 [5/13/2024 4:07 PM]
06-03-2024	AH		INO	Inovio Pharmaceuticals, Inc.	217.25	N/A	-1.58	-2.52	Inovio Pharmaceuticals GAAP EPS of -$1.10 beats by $0.14, revenue of $103M [3/6/2024 4:12 PM]	9.04	-0.83 (-8.41%)	9.65	-0.22 (-2.23%)	3.89 - 14.88	809,916	470,000	4,609
Inovio Pharmaceuticals GAAP EPS of -$1.10 beats by $0.14, revenue of $103k [3/6/2024 4:12 PM]
09-11-2023	AH		INO	Inovio Pharmaceuticals, Inc.	102.14	-0.09	-0.13	-0.15	Inovio Pharmaceuticals Non-GAAP EPS of -$0.09 beats by $0.04, revenue of $0.39M beats by $0.27M [11/9/2023 4:09 PM]	0.3461	-0.02 (-4.42%)	0.36	0.0 (-0.72%)	0.32 - 2.61	3,827,059	2,260,000	91,084
Inovio Pharmaceuticals Non-GAAP EPS of -$0.09 beats by $0.04, revenue of $0.39M beats by $0.27M [11/9/2023 4:09 PM] Inovio files for $300M mixed shelf [11/9/2023 6:15 PM]
09-08-2023	AH		INO	Inovio Pharmaceuticals, Inc.	111.66	-0.13	-0.14	-0.46	Inovio Pharmaceuticals GAAP EPS of -$0.13 beats by $0.01, revenue of $0.23M misses by $0.03M [8/9/2023 4:07 PM]	0.4491	0.05 (11.19%)	0.41	0.01 (1.56%)	0.38 - 2.82	4,440,480	2,660,000	28,164
Inovio Pharmaceuticals GAAP EPS of -$0.13 beats by $0.01, revenue of $0.23M misses by $0.03M [8/9/2023 4:07 PM]
10-05-2023	AH	4:05 PM ET (May 10)	INO	Inovio Pharmaceuticals, Inc.	218.42	-0.16	-0.14	-0.36	Inovio Pharmaceuticals GAAP EPS of -$0.16 misses by $0.02, revenue of $0.11M misses by $0.17M [5/10/2023 4:09 PM]	0.8007	-0.01 (-1.10%)	0.80	-0.01 (-1.19%)	0.69 - 2.82	3,835,678	4,390,000	22,939
Inovio Pharmaceuticals GAAP EPS of -$0.16 misses by $0.02, revenue of $0.11M misses by $0.17M [5/10/2023 4:09 PM]
01-03-2023	AH	4:05 PM ET (Mar 1)	INO	Inovio Pharmaceuticals, Inc.	349.28	-0.21	-0.16	-0.50	Inovio Pharmaceuticals GAAP EPS of -$1.17 misses by $0.06, revenue of $10.26M misses by $0.29M [3/1/2023 4:08 PM]	1.31	0.07 (6.05%)	1.28	0.04 (3.23%)	1.19 - 4.00	2,925,226	3,900,000	36,127
Inovio Pharmaceuticals GAAP EPS of -$1.17 misses by $0.06, revenue of $10.26M misses by $0.29M [3/1/2023 4:08 PM] Inovio stock rises amid mixed trial results for cervical lesions drug; Q4 clinical updates [3/2/2023 1:32 PM]
08-11-2022	AH	4:05 PM ET (Nov 8)	INO	Inovio Pharmaceuticals, Inc.	533.72	-0.15	-0.29	-0.29	Inovio Pharmaceuticals GAAP EPS of -$0.15 beats by $0.15, revenue of $9.15M [11/8/2022 4:08 PM]	2.19	0.05 (2.57%)	2.12	-0.02 (-0.93%)	1.38 - 7.77	7,598,811	6,640,000	16,619
Inovio Pharmaceuticals GAAP EPS of -$0.15 beats by $0.15, revenue of $9.15M [11/8/2022 4:08 PM] Inovio Pharmaceuticals stock rises on Q3 profit beat, raised cash runway guidance [11/9/2022 1:10 PM]
09-08-2022	AH	4:05 PM ET (Aug 9)	INO	Inovio Pharmaceuticals, Inc.	437.47	-0.46	-0.30	-0.39	Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M [8/9/2022 4:12 PM]	2.59	0.49 (23.33%)	2.21	0.11 (5.24%)	1.38 - 9.96	10,004,481	5,790,000	47,446
Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M [8/9/2022 4:12 PM] Inovio beats on the top line but misses on the bottom; quarterly net loss widens 32% [8/9/2022 5:07 PM] INOVIO Reports Financial Results and Highlights for the Second Quarter 2022 [Aug-09-22 04:05PM]
10-05-2022	AH	4:05 PM ET (May 10)	INO	Inovio Pharmaceuticals, Inc.	589.93	-0.36	-0.28	-0.27	Inovio Pharmaceuticals Non-GAAP EPS of -$0.36, revenue of $0.2M [5/10/2022 4:10 PM]	1.80	-0.68 (-27.51%)	2.03	-0.46 (-18.48%)	1.60 - 10.33	16,142,344	4,150,000	189,943
Jacqueline Shea named new CEO of Inovio [5/10/2022 4:12 PM] Inovio Pharmaceuticals Non-GAAP EPS of -$0.36, revenue of $0.2M [5/10/2022 4:10 PM] Inovio Pharmaceuticals falls 20% on Q1 misses, announcement of new CEO [5/10/2022 4:49 PM] Inovio downgraded at Oppenheimer as CEO departure adds uncertainty [5/11/2022 9:28 AM] Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates [May-09-22 08:25AM] Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates [May-10-22 05:35PM] UPDATE 2-Inovio to discontinue COVID vaccine trial, appoints Jacqueline Shea as CEO [May-10-22 04:46PM] INOVIO Reports First Quarter 2022 Financial Results and Program Developments [May-10-22 04:05PM] INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer [May-10-22 04:05PM] Dow Futures Little Changed Ahead of Key Inflation Data [May-10-22 02:46PM] Inovio lets go of CEO, to stop work on COVID-19 vaccine and instead focus on booster [May-11-22 08:16AM] Inovio's Kim out as CEO, company shifts focus from Covid-19 vaccine to booster [May-11-22 10:10AM]
01-03-2022	AH	4:05 PM ET (Mar 1)	INO	Inovio Pharmaceuticals, Inc.	677.44	-0.50	-0.33	-0.14	Inovio Pharmaceuticals GAAP EPS of -$1.45 misses by $0.19, revenue of $1.77M beats by $0.31M [3/1/2022 4:11 PM]	3.04	-0.20 (-6.33%)	2.99	-0.25 (-7.72%)	2.76 - 11.00	6,495,794	3,800,000	121,030
Inovio Pharmaceuticals GAAP EPS of -$1.45 misses by $0.19, revenue of $1.77M beats by $0.31M [3/1/2022 4:11 PM] Inovio Pharmaceuticals results miss on the bottom line; shares down 9% [3/1/2022 4:42 PM] Inovio COVID vaccine weaker vs Omicron in lab test; phase 3 trial enrollment paused [3/2/2022 4:56 AM] 2 Money-Burning Biotech Stocks to Avoid [Mar-01-22 08:45AM] INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results [Mar-01-22 04:05PM] UPDATE 1-Inovio says lab tests show COVID vaccine weaker against Omicron [Mar-01-22 04:37PM] UPDATE 2-Inovio lab tests show COVID vaccine weaker against Omicron, trial enrollment paused [Mar-01-22 04:37PM] Inovio Pharmaceuticals (INO) Reports Q4 Loss, Tops Revenue Estimates [Mar-01-22 06:05PM] Inovio Pharmaceuticals (INO) Q4 2021 Earnings Call Transcript [Mar-01-22 10:30PM] Inovio adopts new strategy in pursuit of regulatory approval for experimental Covid-19 vaccine [Mar-02-22 10:32AM] Why Inovio Stock Tumbled on a Good Day for the Market Wednesday [Mar-02-22 04:12PM]
09-11-2021	AH	4:05 PM ET (Nov 9)	INO	Inovio Pharmaceuticals, Inc.	1,490	-0.29	-0.33	-0.22	Inovio Pharmaceuticals EPS beats by $0.04, misses on revenue [11/9/2021 4:11 PM]	7.13	0.08 (1.13%)	7.13	0.08 (1.13%)	5.81 - 19.00	7,548,552	4,110,000	61,191
INOVIO wins FDA clearance to proceed with late-stage study for COVID-19 shot [11/9/2021 8:35 AM] Inovio Pharmaceuticals EPS beats by $0.04, misses on revenue [11/9/2021 4:11 PM] Inovio targets H1 2022 to share interim data from late-stage trial for COVID-19 shot [11/9/2021 4:37 PM] Warning: INO is at high risk of performing badly [11/10/2021 4:45 AM] INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S. [Nov-09-21 08:00AM] Inovio says the FDA lifted its 'hold' on the Phase 3 clinical trial for its COVID-19 shot [Nov-09-21 08:20AM] UPDATE 2-U.S. FDA lifts clinical hold on Inovio's COVID-19 vaccine trial [Nov-09-21 08:12AM] FDA Lifts Clinical Hold On Inovio's COVID-19 Vaccine Trial [Nov-09-21 10:51AM] Inovio shares rise after FDA OK to complete testing of its Covid-19 vaccine candidate [Nov-09-21 01:47PM] FDA Gives Inovio Pharmaceuticals the All-Clear to Continue Phase 3 Covid Segment [Nov-09-21 09:11AM] Why Shares of Inovio Pharmaceuticals Rallied Today [Nov-09-21 03:39PM] INOVIO Reports Third Quarter 2021 Financial Results [Nov-09-21 04:05PM] Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates [Nov-09-21 05:25PM] Inovio Pharmaceuticals (INO) Q3 2021 Earnings Call Transcript [Nov-10-21 04:32AM] Why Inovio Stock Is Rising Today [Nov-10-21 12:30PM] Is Inovio Stock A Buy After The FDA Removed Its Hold On Covid Vaccine Testing? [Nov-10-21 02:39PM]
09-08-2021	AH	4:05 PM ET (Aug 9)	INO	Inovio Pharmaceuticals, Inc.	1,930	-0.39	-0.25	-0.23	Inovio Pharmaceuticals EPS misses by $0.14, misses on revenue [8/9/2021 4:07 PM]	8.57	-1.03 (-10.73%)	9.24	-0.36 (-3.75%)	5.81 - 19.66	10,539,791	3,970,000	110,834
Inovio receives regulatory allowance for two INO-4800 studies in China [8/9/2021 8:55 AM] Inovio Pharmaceuticals EPS misses by $0.14, misses on revenue [8/9/2021 4:07 PM] INOVIO says DNA COVID vaccine candidate maintains strong T cell response against delta variant [8/9/2021 4:49 PM] INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate [Aug-09-21 08:00AM] Why Inovio Stock Is Jumping Today [Aug-09-21 01:33PM] INOVIO Reports Second Quarter 2021 Financial Results [Aug-09-21 04:05PM] Inovio focused on launching global COVID-19 vaccine trial next month - CEO [Aug-09-21 05:29PM] UPDATE 1-Inovio focused on launching global COVID-19 vaccine trial next month - CEO [Aug-09-21 05:47PM] Inovio Pharmaceuticals (INO) Reports Q2 Loss, Misses Revenue Estimates [Aug-09-21 06:05PM] Inovio Pharmaceuticals (INO) Q2 2021 Earnings Call Transcript [Aug-10-21 02:31AM] UPDATE 2-Inovio focused on launching global COVID-19 vaccine trial next month - CEO [Aug-09-21 05:47PM] Why Inovio Pharmaceuticals Is Plunging Today [Aug-10-21 02:22PM] Is Inovio Stock A Buy Or A Sell As Second-Quarter Metrics Come Up Short? [Aug-10-21 03:15PM]
10-05-2021	AH	4:15 PM ET (May 10)	INO	Inovio Pharmaceuticals, Inc.	1,360	-0.27	-0.18	-0.26	Inovio Pharmaceuticals EPS misses by $0.08, misses on revenue [5/10/2021 4:07 PM]	6.49	-0.18 (-2.77%)	5.89	-0.78 (-11.69%)	5.81 - 33.79	8,743,472	7,830,000	486,738
INOVIO shares rise on positive data from mid-stage COVID-19 trial [5/10/2021 8:21 AM] Inovio Pharmaceuticals EPS misses by $0.08, misses on revenue [5/10/2021 4:07 PM] INOVIO posts wider Q1 net loss as R&D expenses ramp [5/10/2021 4:35 PM] INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine [May-10-21 08:00AM] Inovio's stock is up after it shares new data from Phase 2 clinical trial for its COVID-19 vaccine candidate [May-10-21 08:28AM] Inovio's DNA COVID-19 Vaccine Candidate Triggers Immune Response In Pivotal Study [May-10-21 09:58AM] INOVIO Reports First Quarter 2021 Financial Results [May-10-21 04:05PM] Inovio Falls on Wider Loss; Progress Shown in COVID Vaccine Trial [May-10-21 12:42PM] Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates [May-10-21 06:05PM] Inovio Pharmaceuticals (INO) Q1 2021 Earnings Call Transcript [May-11-21 03:01AM] Novavax, Inovio Stocks Hammered As Covid Vaccine News Disappoints [May-11-21 10:40AM] Is Inovio Stock A Sell On Underwhelming Covid Vaccine Test Results? [May-11-21 12:45PM]
01-03-2021	AH	4:05 PM ET (Mar 1)	INO	Inovio Pharmaceuticals, Inc.	2,350	-0.14	-0.22	-0.32	Inovio Pharmaceuticals EPS beats by $0.08, beats on revenue [3/1/2021 4:17 PM]	10.04	-1.56 (-13.49%)	11.00	-0.60 (-5.17%)	3.83 - 33.79	19,775,457	13,309,840	482,100
Inovio Pharmaceuticals EPS beats by $0.08, beats on revenue [3/1/2021 4:17 PM] Inovio shares slip afterhours despite positive phase 3 results for VGX-3100 [3/1/2021 5:35 PM] The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data [Mar-02-21 08:01AM] Why Inovio's Positive Q4 Update Didn't Impress Investors [Mar-02-21 06:02AM] Inovio Reports Q4 Earnings Beat, Mixed REVEAL 1 Data And Coronavirus Vaccine Update [Mar-01-21 05:00PM] Recap: Inovio Pharmaceuticals Q4 Earnings [Mar-01-21 04:35PM] INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results [Mar-01-21 04:15PM]
09-11-2020	AH	4:05 PM ET (Nov 9)	INO	Inovio Pharmaceuticals, Inc.	1,810	-0.22	-0.18	-0.27	Inovio Pharmaceuticals EPS beats by $0.30, misses on revenue [11/9/2020 4:06 PM]	11.53	3.03 (35.65%)	8.99	0.49 (5.76%)	2.19 - 33.79	34,105,635	7,636,011	183,457

10-08-2020	AH	4:05 PM ET (Aug 10)	INO	Inovio Pharmaceuticals, Inc.	3,210	-0.23	-0.18	-0.30	Inovio Pharmaceuticals EPS misses by $0.66, misses on revenue [8/10/2020 4:10 PM]	15.03	-3.96 (-20.85%)	16.49	-2.50 (-13.16%)	1.92 - 33.79	30,351,556	19,297,204	2,035,589